Trump ally Steve Daines rejects claims of talks with KMT leader
Republican Senator Steve Daines said he did not meet with Cheng Li-wun, the leader of Taiwan’s main opposition Kuomintang party, during her US visit earlier this month despite Cheng’s statements to the contrary, saying she met only with members of his staff. “She met my staff. Sh

AdvertisementUS-China relationsUSTrump ally Steve Daines rejects claims of talks with KMT leaderMontana lawmaker says Kuomintang chief Cheng Li-wun met only his staff, contradicting her account of talks in Washington earlier this month3-MIN READ3-MIN ListenNayan Sethin WashingtonPublished: 5:39am, 1 Jul 2026Updated: 5:46am, 1 Jul 2026Republican Senator Steve Daines said he did not meet with Cheng Li-wun, the leader of Taiwan’s main opposition Kuomintang party, during her US visit earlier this month despite Cheng’s statements to the contrary, saying she met only with members of his staff.“She met my staff. She did not meet me,” the conservative lawmaker from Montana told the South China Morning Post on Monday.
Cheng visited Washington earlier this month as part of a broader effort to strengthen ties with US policymakers during a multi-city two-week tour that also included San Francisco, Boston and New York.In a June 12 Facebook post, Cheng listed Daines among the lawmakers she visited in Washington, which also included Republican Senator Dan Sullivan and GOP House members from Tennessee, John Rose and Chuck Fleischmann.“We exchanged views on topics such as US-Taiwan relations, Indo-Pacific security, regional stability, and the cross-strait situation,” she posted.
Taiwanese media outlet United Daily News also reported that Daines had focused on energy and resource security instead of cross-strait relations in his talks with Cheng.AdvertisementSelect VoiceSelect Speed0.8x0.
9x1.0x1.1x1.
2x1.5x1.75x00:0000:001.
00x
Đọc thêm từ Tài chính
Nike forecasts surprise fall in full-year revenue, shares tumble 4%
Sales continued to fall in China, which has been a weak spot for Nike in recent quarters.
Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
SAN DIEGO and TORONTO, June 30, 2026 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagno
